ghk-cu clinical trials dosage humans human studies or trial dose aka the beauty peptide., I've got immunogenicity of ghk-cu or antibodies

Chiodin, G

The dose size stays 10 units throughout

The "minimal initial benefit" group (approximately 5-10% of users) reported limited improvements during treatment making discontinuation effects irrelevant, typically explained by inadequate product quality with degraded or low-concentration GHK-Cu, inappropriate application technique reducing absorption, unrealistic expectations exceeding what any topical can achieve, severe underlying pathology requiring medical intervention beyond cosmetic peptides, or individual non-responsiveness to copper peptide treatment for genetic or physiological reasons

2006 Apr;97(2):303-9 (2) Shustanova TA, Bondarenko TI, Milyutina NP, Mikhaleva II